Lisa Wilson | In-Site Communications |
Brian Markison | Chief Executive Officer |
James Schaub | Chief Operating Officer |
Michael DePetris | Principal Accounting Officer |
Louise Chen | Cantor Fitzgerald |
John Vandermosten | Zacks SCR |
Michaela Diverio | Barclays |
Jorge King | H.C. Wainwright |
Good morning, everyone. My name is Todd, and I will be your conference operator. At this time, I'd like to welcome everyone to the RVL Pharmaceuticals First Quarter 2023 Financial Results Call. All lines have been placed on mute to prevent any background noise. After the speakers’ remarks there will be a question-and-answer period.